Anadys Pharmaceuticals Augments Management Team and Board of Directors

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced the following additions and changes to its management team and Board of Directors:

• Kevin L. Eastwood has joined Anadys as Senior Vice President, Corporate Development
• James Appleman, Ph.D. has been promoted to Senior Vice President, Research and Chief Scientific Officer
• James L. Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer, has been appointed to the Company's Board of Directors
• Stelios Papadopoulos, Ph.D. has been named Chairman of the Board

"I am delighted with the addition of Kevin Eastwood to our management team and the additional responsibilities for Drs. Appleman, Freddo and Papadopoulos," said Steve Worland, Ph.D., Anadys' President and CEO. "With these changes in place, we are well-positioned to execute our corporate objectives in the coming year."

Mr. Eastwood, who joins Anadys from Ambrx, Inc., will be responsible for the Company's business development and strategic planning activities, reporting to Steve Worland, Ph.D., President and Chief Executive Officer. Mr. Eastwood has held a number of prior business development positions, including the senior corporate development positions at Ambrx, Inc. and Achillion Pharmaceuticals, Inc. In these positions he was responsible for executing business transactions with a number of leading biotechnology and pharmaceutical companies, including Pfizer, Inc., Merck and Co., Inc., Eli Lilly and Company, and Gilead Sciences, Inc. Mr. Eastwood began his pharmaceuticals career in sales and marketing at Marion Laboratories and transitioned to business development while at Agouron Pharmaceuticals, Inc., now a part of Pfizer. He holds a B.S. in Biology from Missouri State University.